Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities
SP Hack, AX Zhu, Y Wang - Frontiers in Immunology, 2020 - frontiersin.org
Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Abstract Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall
survival of a subset of patients across multiple solid tumour types, but other patients can …
survival of a subset of patients across multiple solid tumour types, but other patients can …
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open …
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open …
Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses
Summary CD4 T follicular helper (TFH) cells support B cells, which are critical for germinal
center (GC) formation, but the importance of TFH-B cell interactions in cancer is unclear. We …
center (GC) formation, but the importance of TFH-B cell interactions in cancer is unclear. We …
Inferring gene expression from cell-free DNA fragmentation profiles
Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …
noninvasive cancer detection. Chromatin fragmentation features have previously been …
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III …
WZ Zhong, Q Wang, WM Mao, ST Xu, L Wu… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials. gov identifier: NCT01405079), a
randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved …
randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved …
Impact of intensity-modulated radiation therapy technique for locally advanced non–small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 …
SG Chun, C Hu, H Choy, RU Komaki… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Although intensity-modulated radiation therapy (IMRT) is increasingly used to treat
locally advanced non–small-cell lung cancer (NSCLC), IMRT and three-dimensional …
locally advanced non–small-cell lung cancer (NSCLC), IMRT and three-dimensional …
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label …
WZ Zhong, Q Wang, WM Mao, ST Xu, L Wu… - The Lancet …, 2018 - thelancet.com
Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …
Clinical implications of plasma-based genoty** with the delivery of personalized therapy in metastatic non–small cell lung cancer
C Aggarwal, JC Thompson, TA Black, SI Katz… - JAMA …, 2019 - jamanetwork.com
Importance The clinical implications of adding plasma-based circulating tumor DNA next-
generation sequencing (NGS) to tissue NGS for targetable mutation detection in non–small …
generation sequencing (NGS) to tissue NGS for targetable mutation detection in non–small …
Lower airway dysbiosis affects lung cancer progression
In lung cancer, enrichment of the lower airway microbiota with oral commensals commonly
occurs, and ex vivo models support that some of these bacteria can trigger host …
occurs, and ex vivo models support that some of these bacteria can trigger host …